Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

164.17 -1.56 (-0.94%)
Official Closing Price Updated: 6:30 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗
The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug. 
Via Stocktwits
News headline image
Why Did QURE Stock Almost Halve Pre-Market Today? ↗
uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130. 
Via Stocktwits
News headline image
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction ↗
The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027. 
Via Stocktwits
News headline image
IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗
The company said it plans to submit a biologics license application by the fourth quarter of 2026. 
Via Stocktwits
Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗
Via Stocktwits
News headline image
CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗
The company said it has enrolled patients in its late-stage program ahead of schedule. 
Via Stocktwits
Topics Earnings
News headline image
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗
Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗
According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024. 
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
The biotech company reported statistically significant Phase 3 data for QTORIN gel. 
Via Stocktwits
News headline image
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder ↗
The company applied for approval of the gene therapy in the treatment of Glycogen Storage Disease Type Ia or Von Gierke disease. 
Via Stocktwits
News headline image
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗
ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time. 
Via Stocktwits
News headline image
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? ↗
Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10. 
Via Stocktwits
Topics Earnings Intellectual Property
News headline image
GRAL Stock Slumps After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses ↗
The trial did not show a statistically significant reduction in Stage III-IV cancer diagnoses, the company said. 
Via Stocktwits
Topics Artificial Intelligence Death
News headline image
ARDX Stock Slips After Hours As Q4 Earnings Disappoint: Retail Sees Ibsrela Driving Outperformance In Time ↗
The company reported no earnings for the fourth quarter, compared to an analyst estimate of $0.01 per share. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗
The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe. 
Via Stocktwits
News headline image
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition ↗
The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio. 
Via Stocktwits
News headline image
IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally ↗
The European Commission granted conditional marketing authorization to ImmunityBio’s Anktiva, implying that it wants more data from the company. 
Via Stocktwits
News headline image
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗
The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks. 
Via Stocktwits
News headline image
IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU ↗
Retail investors are now looking forward to a full approval of Anktiva in the EU for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. 
Via Stocktwits
News headline image
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty ↗
Ultragenyx said on Thursday that the FDA has again refused approval for UX111 in the treatment of Sanfilippo syndrome type A. 
Via Stocktwits
News headline image
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗
The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity. 
Via Stocktwits
News headline image
Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Sector Alert: 4 Healthcare ETFs Poised for Explosive Growth Now ↗
Healthcare stocks have lagged the market for years, but 2026 is looking much better. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Why Did UPB Stock Pop 20% In Pre-Market Today? ↗
The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma. 
Via Stocktwits
News headline image
Why Did RGNX Shares Plummet 19% After-Hours Today? ↗
REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial. 
Via Stocktwits
News headline image
MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products ↗
According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? ↗
REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases. 
Via Stocktwits
News headline image
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus. 
Via Stocktwits
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗
The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.